Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Lammerts van Bueren Jj"'
Autor:
van de Winkel Jg, Lammerts van Bueren Jj, Thomas Valerius, Brännström A, Paul W. H. I. Parren, Wim K. Bleeker, Magnus Jansson, Tanja Schneider-Merck, Matthias Peipp
Publikováno v:
Proceedings of the National Academy of Sciences. 109:5548-5548
The epidermal growth factor receptor (EGFR) activates cellular pathways controlling cell proliferation, differentiation, migration, and survival. It thus represents a valid therapeutic target for treating solid cancers. Here, we used an electron micr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93889725ebf37843c160582c5792df16
https://doi.org/10.1073/pnas.1203736109
https://doi.org/10.1073/pnas.1203736109
Autor:
de Bono JS; The Institute of Cancer Research, Royal Cancer Hospital, London, UK., Harris JR; Genmab, Plainsboro, New Jersey, USA., Burm SM; Genmab, Utrecht, The Netherlands., Vanderstichele A; Department of Gynaecology and Obstetrics, Division of Gynaecologic Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium., Houtkamp MA; Genmab, Utrecht, The Netherlands., Aarass S; Genmab, Plainsboro, New Jersey, USA.; Genmab, Utrecht, The Netherlands., Riisnaes R; The Institute of Cancer Research, Royal Cancer Hospital, London, UK., Figueiredo I; The Institute of Cancer Research, Royal Cancer Hospital, London, UK., Nava Rodrigues D; The Institute of Cancer Research, Royal Cancer Hospital, London, UK., Christova R; The Institute of Cancer Research, Royal Cancer Hospital, London, UK., Olbrecht S; Department of Gynaecology and Obstetrics, Division of Gynaecologic Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium., Niessen HWM; Department of Pathology, VU Medical Center, Amsterdam, The Netherlands., Ruuls SR; Lava Therapeutics, Utrecht, The Netherlands., Schuurhuis DH; Genmab, Utrecht, The Netherlands., Lammerts van Bueren JJ; Merus, Utrecht, The Netherlands., Breij ECW; Genmab, Utrecht, The Netherlands., Vergote I; Department of Gynaecology and Obstetrics, Division of Gynaecologic Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
Publikováno v:
Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2023 Feb; Vol. 6 (2), pp. e1699. Date of Electronic Publication: 2022 Aug 13.
Autor:
Schram AM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York., Odintsov I; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Espinosa-Cotton M; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Khodos I; Anti-tumor Core Facility, Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Sisso WJ; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Mattar MS; Anti-tumor Core Facility, Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Lui AJW; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Vojnic M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Shameem SH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Chauhan T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Torrisi J; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Ford J; Merus N.V., Utrecht, the Netherlands., O'Connor MN; Merus N.V., Utrecht, the Netherlands., Geuijen CAW; Merus N.V., Utrecht, the Netherlands., Schackmann RCJ; Merus N.V., Utrecht, the Netherlands., Lammerts van Bueren JJ; Merus N.V., Utrecht, the Netherlands., Wasserman E; Merus N.V., Utrecht, the Netherlands., de Stanchina E; Anti-tumor Core Facility, Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., O'Reilly EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York., Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Drilon A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York., Somwar R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Publikováno v:
Cancer discovery [Cancer Discov] 2022 May 02; Vol. 12 (5), pp. 1233-1247.
Autor:
Herpers B; OcellO BV, Leiden, The Netherlands.; Crown Bioscience Netherlands BV, Leiden, The Netherlands., Eppink B; Merus NV, Utrecht, The Netherlands., James MI; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain., Cortina C; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBERONC, Madrid, Spain., Cañellas-Socias A; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBERONC, Madrid, Spain., Boj SF; Hubrecht Organoid Technology (HUB), Utrecht, the Netherlands., Hernando-Momblona X; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBERONC, Madrid, Spain., Glodzik D; Wellcome Sanger Institute, Hinxton, UK.; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA., Roovers RC; Merus NV, Utrecht, The Netherlands., van de Wetering M; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.; Oncode Institute, Hubrecht Institute, Utrecht, the Netherlands., Bartelink-Clements C; Merus NV, Utrecht, The Netherlands., Zondag-van der Zande V; Merus NV, Utrecht, The Netherlands., Mateos JG; OcellO BV, Leiden, The Netherlands.; Crown Bioscience Netherlands BV, Leiden, The Netherlands., Yan K; OcellO BV, Leiden, The Netherlands.; Crown Bioscience Netherlands BV, Leiden, The Netherlands., Salinaro L; OcellO BV, Leiden, The Netherlands., Basmeleh A; Merus NV, Utrecht, The Netherlands., Fatrai S; Merus NV, Utrecht, The Netherlands., Maussang D; Merus NV, Utrecht, The Netherlands., Lammerts van Bueren JJ; Merus NV, Utrecht, The Netherlands., Chicote I; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Serna G; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Cabellos L; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain., Ramírez L; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain., Nuciforo P; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Salazar R; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain., Santos C; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain., Villanueva A; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.; Xenopat SL, Parc Cientific de Barcelona (PCB), Barcelona, Spain., Stephan-Otto Attolini C; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain., Sancho E; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBERONC, Madrid, Spain., Palmer HG; CIBERONC, Madrid, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain., Tabernero J; CIBERONC, Madrid, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain., Stratton MR; Wellcome Sanger Institute, Hinxton, UK., de Kruif J; Merus NV, Utrecht, The Netherlands., Logtenberg T; Merus NV, Utrecht, The Netherlands., Clevers H; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.; Oncode Institute, Hubrecht Institute, Utrecht, the Netherlands., Price LS; OcellO BV, Leiden, The Netherlands.; Crown Bioscience Netherlands BV, Leiden, The Netherlands., Vries RGJ; Hubrecht Organoid Technology (HUB), Utrecht, the Netherlands., Batlle E; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain. eduard.batlle@irbbarcelona.org.; CIBERONC, Madrid, Spain. eduard.batlle@irbbarcelona.org.; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain. eduard.batlle@irbbarcelona.org., Throsby M; Merus NV, Utrecht, The Netherlands. M.Throsby@merus.nl.
Publikováno v:
Nature cancer [Nat Cancer] 2022 Apr; Vol. 3 (4), pp. 418-436. Date of Electronic Publication: 2022 Apr 25.
Autor:
Overdijk MB; Genmab, 3584 CM Utrecht, the Netherlands;, Jansen JH; Immunotherapy Laboratory, Laboratory for Translational Immunology, University Medical Center, 3584 CX Utrecht, the Netherlands;, Nederend M; Immunotherapy Laboratory, Laboratory for Translational Immunology, University Medical Center, 3584 CX Utrecht, the Netherlands;, Lammerts van Bueren JJ; Genmab, 3584 CM Utrecht, the Netherlands;, Groen RW; Department of Cell Biology, University Medical Center, 3584 CX Utrecht, the Netherlands;, Parren PW; Genmab, 3584 CM Utrecht, the Netherlands; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark; and Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2300 RC Leiden, the Netherlands., Leusen JH; Immunotherapy Laboratory, Laboratory for Translational Immunology, University Medical Center, 3584 CX Utrecht, the Netherlands; jleusen@umcutrecht.nl., Boross P; Immunotherapy Laboratory, Laboratory for Translational Immunology, University Medical Center, 3584 CX Utrecht, the Netherlands;
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2016 Aug 01; Vol. 197 (3), pp. 807-13. Date of Electronic Publication: 2016 Jun 17.
Autor:
Drent E; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands Departments of Clinical Chemistry and Hematology, Utrecht, the Netherlands., Groen RW; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands Department of Cell Biology, University Medical Center, Utrecht, the Netherlands., Noort WA; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands Department of Cell Biology, University Medical Center, Utrecht, the Netherlands., Themeli M; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands., Lammerts van Bueren JJ; Genmab, Utrecht, the Netherlands., Parren PW; Genmab, Utrecht, the Netherlands Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, the Netherlands., Kuball J; Department of Hematology, University Medical Center, Utrecht, the Netherlands., Sebestyen Z; Department of Immunology, University Medical Center Utrecht, the Netherlands., Yuan H; Xpand Biotechnology BV, Bilthoven, the Netherlands., de Bruijn J; Xpand Biotechnology BV, Bilthoven, the Netherlands The School of Engineering and Materials Science, Queen Mary University of London, UK., van de Donk NW; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands., Martens AC; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands Department of Cell Biology, University Medical Center, Utrecht, the Netherlands Department of Immunology, University Medical Center Utrecht, the Netherlands., Lokhorst HM; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands Department of Hematology, University Medical Center, Utrecht, the Netherlands., Mutis T; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands Departments of Clinical Chemistry and Hematology, Utrecht, the Netherlands t.mutis@vumc.nl.
Publikováno v:
Haematologica [Haematologica] 2016 May; Vol. 101 (5), pp. 616-25. Date of Electronic Publication: 2016 Feb 08.
Autor:
van de Donk NW; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands., Janmaat ML; Genmab, Utrecht, the Netherlands., Mutis T; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands., Lammerts van Bueren JJ; Genmab, Utrecht, the Netherlands., Ahmadi T; Janssen Research and Development, Spring House, PA, USA., Sasser AK; Janssen Research and Development, Spring House, PA, USA., Lokhorst HM; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands., Parren PW; Genmab, Utrecht, the Netherlands.; Department of Cancer and inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.
Publikováno v:
Immunological reviews [Immunol Rev] 2016 Mar; Vol. 270 (1), pp. 95-112.
Autor:
Oostendorp M; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht., Lammerts van Bueren JJ; Genmab, Utrecht, The Netherlands., Doshi P; Janssen R&D LLC, Spring House (Ambler), Pennsylvania., Khan I; Janssen R&D LLC, Spring House (Ambler), Pennsylvania., Ahmadi T; Janssen R&D LLC, Spring House (Ambler), Pennsylvania., Parren PW; Genmab, Utrecht, The Netherlands.; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands., van Solinge WW; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht., De Vooght KM; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht.
Publikováno v:
Transfusion [Transfusion] 2015 Jun; Vol. 55 (6 Pt 2), pp. 1555-62. Date of Electronic Publication: 2015 May 18.
Autor:
Nijhof IS; Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, The Netherlands Department of Hematology, University Medical Center Utrecht, The Netherlands Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Lammerts van Bueren JJ; Genmab, Utrecht, The Netherlands., van Kessel B; Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, The Netherlands Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Andre P; Research & Development, Innate Pharma, Marseille, France., Morel Y; Research & Development, Innate Pharma, Marseille, France., Lokhorst HM; Department of Hematology, University Medical Center Utrecht, The Netherlands Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., van de Donk NW; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Parren PW; Genmab, Utrecht, The Netherlands Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark., Mutis T; Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, The Netherlands Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands t.mutis@vumc.nl.
Publikováno v:
Haematologica [Haematologica] 2015 Feb; Vol. 100 (2), pp. 263-8. Date of Electronic Publication: 2014 Dec 15.
Autor:
Overdijk MB; a Genmab ; Utrecht , The Netherlands., Verploegen S, Bögels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, Parren PW
Publikováno v:
MAbs [MAbs] 2015; Vol. 7 (2), pp. 311-21.